Eukaryotic Initiation Factor (eIF)
Eukaryotic initiation factors (eIFs) are proteins involved in the initiation phase of eukaryotic translation. These proteins help stabilize the formation of the functional ribosome around the start codon and also provide regulatory mechanisms in translation initiation.
Eukaryotic initiation factor 2B (eIF2B) is a guanine nucleotide-exchange factor which mediates the exchange of GDP (bound to initiation factor eIF2) for GTP, thus regenerating the active [eIF2.GTP] complex that is required for peptide-chain initiation. The activity of eIF2B is a key control point for eukaryotic protein synthesis and is altered in response to viral infection, hormones, nutrients, growth factors and certain stresses.
Eukaryotic translation initiation factor 4E (eIF4E) is best known for its function in the initiation of protein synthesis on capped mRNAs in the cytoplasm. Eukaryotic initiation factor (elF) 4A functions as a subunit of the initiation factor complex elF4F, which mediates the binding of mRNA to the ribosome.
All Product Categories
-
Eukaryotic Initiation Factor (eIF) Inhibitors
(78)
View all products
-
Eukaryotic Initiation Factor (eIF) Antagonist
(1)
View all products
-
Eukaryotic Initiation Factor (eIF) Activators
(29)
View all products
-
Eukaryotic Initiation Factor (eIF) Modulators
(13)
View all products
-
Eukaryotic Initiation Factor (eIF) Chemicals
(3)
View all products
-
Eukaryotic Initiation Factor (eIF) Degraders
(2)
View all products
-
Eukaryotic Initiation Factor (eIF) Control
(1)
View all products
-
Eukaryotic Initiation Factor (eIF) Ligands
(3)
View all products
-
Eukaryotic Initiation Factor (eIF) Verwandte Produkte (140)
Verwandte Produkte (140)
-
Antibodies (15)
-
GCN2iB acetate
0 ImagesArt. -Nr.: HY-112654ACAS. Nr.: 2183470-13-3GCN2iB acetate is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM. GCN2iB acetate inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB acetate enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB acetate increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB acetate can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy.
-
ETC-501
0 ImagesArt. -Nr.: HY-181627CAS. Nr.: 3094990-88-9ETC-501 is a blood-brain barrier-permeable, orally active, and selective MNK1/MNK2 inhibitor, with an IC50 of 0.033 μM against MNK1 and 0.111 μM against MNK2. ETC-501 inhibits glioblastoma cell proliferation, impairs DNA damage repair function, delays cell cycle progression, and suppresses ribosome biogenesis. ETC-501 enhances Temozolomide (HY-17364)-induced cellular senescence, attenuates the senescence-associated secretory phenotype, and increases cellular sensitivity to Navitoclax (HY-10087). ETC-501 is applicable to research related to glioblastoma.
-
HD202A
0 ImagesArt. -Nr.: HY-182046CAS. Nr.: 2930131-74-9HD202A is an orally active, selective dual inhibitor of MNK1/MNK2 (with IC50 values of 6.09 nM and 8.06 nM, and Kd values of 1.913 μM and 5.244 μM, respectively) that inhibits the MNK-eIF4E signaling pathway. By downregulating perilipin 2 and SCD1, while upregulating adipose triglyceride lipase and PPARγ coactivator 1α, HD202A enhances mitochondrial fatty acid oxidation and redox homeostasis. HD202A effectively suppresses body weight gain, hepatic lipid accumulation and elevation of serum lipids, significantly improves glucose tolerance and insulin sensitivity of the organism, and ameliorates inflammatory features. With these comprehensive pharmacological activities, HD202A exhibits great application potential in studies of metabolic dysfunction-associated steatotic liver disease.
-
(+)-Rocaglamide
0 ImagesArt. -Nr.: HY-19356BCAS. Nr.: 1699754-37-4(+)-Rocaglamide is the dextrorotatory enantiomer of Rocaglamide (HY-19356). Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of 50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.
-
eIF4A-IN-2
0 ImagesArt. -Nr.: HY-176843CAS. Nr.: 3083974-69-7eIF4A-IN-2 (Compound 93) is an Eukaryotic translation initiation factor 4A (eIF4A) inhibitor. eIF4A-IN-2 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs).
-
eIF4A-IN-1
0 ImagesArt. -Nr.: HY-176842CAS. Nr.: 3083974-55-1eIF4A-IN-1 (Compound 79) is an eIF4A inhibitor that inhibits protein translation. eIF4A-IN-1 canb be used in gastric cancer research.
-
MNK1/2-IN-10
0 ImagesArt. -Nr.: HY-182939MNK1/2-IN-10 is an orally active, selective MNK1/MNK2 inhibitor, with an IC50 of 10.84 nM for MNK1 and an IC50 of 12.81 nM for MNK2. MNK1/2-IN-10 inhibits eIF4E phosphorylation, the NF-κB signaling pathway, macrophage polarization, oxidative stress and the production of pro-inflammatory cytokines. MNK1/2-IN-10 alleviates kidney and spleen damage in LPS (HY-D1056)-induced inflammatory mouse models. Anti-inflammatory agent 115 is applicable for research related to acute inflammation.
-
ISR activator-4
0 ImagesArt. -Nr.: HY-183703ISR activator-4 is an eIF2B modulator and integrated stress response (ISR) activator with a human eIF2B EC50 of 2.2 μM. ISR activator-4 stabilises the inactive I-state of eIF2B, favours formation of the inhibitory eIF2B-eIF2(αP) complex, and attenuates eIF2B's guanine nucleotide exchange factor activity. ISR activator-4 can be used for the research of cancer, neurologic and metabolic disorders.
-
eIF4A3-IN-5
0 ImagesArt. -Nr.: HY-145359CAS. Nr.: 2100145-31-9eIF4A3-IN-5 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), such as eIF4AI and eIF4AII. eIF4A3-IN-5 has the potential for the research of eIF4A dependent diseases, including the research of cancer (extracted from patent US20170145026A1).
-
m7GpppAmpG ammonium solution (100 mM) (GMP like)
0 ImagesArt. -Nr.: HY-145974AGLCAS. Nr.: 3080642-79-8Synonyms: m7G(5')ppp(5')(2'OMeA)pG solution (100 mM) (GMP like)m7GpppAmpG ammonium solution (100 mM) (GMP-like) (m7G(5')ppp(5')(2'OMeA)pG solution (100 mM) (GMP-like)) is a GMP-like grade of m7GpppAmpG ammonium. m7GpppAmpG ammonium (m7G(5')ppp(5')(2'OMeA)pG ammonium) is a trinucleotide 5′ end cap analog. m7GpppAmpG ammonium binds to eIF4E with a KD value of 45.6 nM. m7GpppAmpG ammonium caps RNA with a capping efficiency of 90%. m7GpppAmpG ammonium enhances mRNA stability and translation efficiency. m7GpppAmpG ammonium is used in mRNA therapeutic research.
-
EIF2B-IN-1
0 ImagesArt. -Nr.: HY-179109EIF2B-IN-1 (Compound A) is an eIF2B inhibitor. EIF2B-IN-1 binds eIF2B. EIF2B-IN-1 stabilises the eIF2B decamer and favours inhibitory eIF2B:eIF2(αP) complex formation. EIF2B-IN-1 exhibits weak displacement of ISRIB. EIF2B-IN-1 can be used in the research of integrated stress responses.
-
ISR activator 3
0 ImagesArt. -Nr.: HY-179539CAS. Nr.: 332950-12-6ISR activator 3 (Compound cc81) is the active metabolite of A8. ISR activator 3 activates the integrated stress response (ISR) by binding to RIG-I (KD ≈ 0.55 μM), without inducing lipid droplet clearance. ISR activator 3 enhances the interferon response under viral mimicry signals. ISR activator 3 can be used for research on neurodegenerative diseases and immune stress.
-
HRI Recombinant Human Active Protein Kinase
0 ImagesArt. -Nr.: HY-E70728Heme-regulated inhibitory (HRI) is an eIF2α kinase, which induces a cytosolic unfolded protein response to prevent aggregation of innate immune signalosomes. HRI Recombinant Human Active Protein Kinase is a recombinant HRI protein that can be used to study HRI-related functions.
-
eIF4E-IN-4
0 ImagesArt. -Nr.: HY-148664CAS. Nr.: 1373822-39-9eIF4E-IN-4 (Compound 33) is a selective inhibitor of eukaryotic initiation factor 4E (eIF4E) with biochemical activity value of 95 nM. eIF4E-IN-4 inhibits cap-dependent mRNA translation with an IC50 value of 2.5 μM. eIF4E-IN-4 can be used for breast cancer, colon cancer, and head and neck cancer study.
-
CDC25A/NF-κB-IN-1
0 ImagesArt. -Nr.: HY-184446CDC25A/NF-κB-IN-1 is an effective dual-target inhibitor of CDC25A and NF-κB, and is a prodrug of Pt(IV). CDC25A/NF-κB-IN-1 has anticancer activity and low cytotoxicity to normal cells. CDC25A/NF-κB-IN-1 can trigger a variety of anticancer mechanisms, including S phase cell cycle arrest, mitochondrial endogenous apoptosis, endoplasmic reticulum stress, autophagy-dependent ferroptosis. CDC25A/NF-κB-IN-1 has good safety and can be used for ovarian cancer research.
-
eIF4A3-IN-6
0 ImagesArt. -Nr.: HY-145360CAS. Nr.: 2100133-77-3eIF4A3-IN-6 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), such as eIF4AI and eIF4AII. eIF4A3-IN-6 has the potential for the research of eIF4A dependent diseases, including the research of cancer (extracted from patent US20170145026A1).
-
ISR activator-5
0 ImagesArt. -Nr.: HY-183704ISR activator-5 is an eIF2B modulator and integrated stress response (ISR) activator. ISR activator-5 stabilises the inactive I-state of eIF2B, inhibits protein synthesis, and activates canonical ISR pathways without inducing eIF2α phosphorylation. ISR activator-5 can be used for the research of cancer, neurologic and metabolic disorders.
-
AMG-34
0 ImagesArt. -Nr.: HY-175880CAS. Nr.: 1644664-11-8AMG-34 is a GCN2-targeting agent with IC50 values of 0.395 μM, 0.010 μM, 1.07 μM and ＞ 10 μM for GCN2, PERK, HRland PKR, respectively.
